PF 5212366

Drug Profile

PF 5212366

Alternative Names: Bivalent recombinant lipoprotein 2086 vaccine; Bivalent recombinant LP2086; Bivalent rLP2086; Bivalent rLP2086 vaccine; MenB-FHbp; Meningococcal B rLP2086 vaccine - Pfizer; Meningococcal group B vaccine - Pfizer; MnB-rLP2086; PF-05212366; PF-5212366; Rlp 2086; rLP2086; TRUMENBA

Latest Information Update: 01 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Meningococcal vaccines; Recombinant proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal group B infections

Most Recent Events

  • 30 May 2017 Registered for Meningococcal group B infections (In adolescents, Prevention, In adults) in European Union (IM)
  • 24 Apr 2017 Pfizer initiates a phase III trial for Meningococcal group B infections (Prevention) in USA (NCT03135834)
  • 24 Mar 2017 The CHMP recommends approval of PF 5212366 for Meningococcal group B infections (In adolescents, Prevention, In adults) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top